Interestingly, in vitro GM102 positively cooperates with pembrolizumab, an anti-PDCD1 (programmed cell death 1) antibody, which is useful in cancers with microsatellite instability (Lynch syndrome) with profiling lymphocytes towards TH1 cells (189, 198). This evidence concerns the gene PDCD1 and cancer.